

Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	1	of	2	Application Number	10/517,564
				Filing Date	December 15, 2005
				First Named Inventor	DeKoning et al.
				Art Unit	4614 1623
				Examiner Name	Lawrence E. Crane
				Attorney Docket Number	Docket 067670-5004-US

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1				T6

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C1	Broeders et al. "A <sup>31</sup> P NMR Stereochemical and Kinetic Study of the Alkaline Hydrolysis of <i>cis</i> -Nucleoside 3',5'-Cyclic Aryl [ <sup>18</sup> O]Monophosphates and Unlabeled Analogs", Amer Chem Society (1992), Vol 114, no. 24, pp 9624-9633			
**	C2	Caesar accession number 1151, AN: 131:32132 CA "Adenosine 3',5'-cyclic phosphates for treatment of ischemic diseases, and for organ preservation"			
**	ee	Caesar accession number 1152, AN: 128:53046 CA "Skin Cosmetics"			
**	ee	Caesar accession number 1153. AN: 115:159682 CA " N6,2'-O-Di-substituted-adenosine-3',5'-cyclic phosphates and their preparation"			
**	ee	Caesar accession number 1155, AN: 114:102710 CA " N6,2'-O-Di-substituted-adenosine-3',5'-cyclic phosphates and their preparation"			
**	ee	Caesar accession number 1796, AN: 96:143250 CA "Carbon-13 NMR spectrum of 2'-fluoro-2'-deoxyadenosine 3',5'-cyclic phosphate"			
**	ee	Caesar accession number 1154, AN:114:143938 CA "Preparation of N6,N6,2'-O-trisubstituted-adenosine-3',5'-cyclic phosphate as drugs"			

Examiner Signature	/Lawrence Crane/	Date Considered	03/18/2010
--------------------	------------------	-----------------	------------

\*EXAMINER: <sup>1</sup> These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

\*\*Incomplete citation: No date of publication or original published source, etc.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./

Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	2	of	2	Application Number	10/517,564
				Filing Date	December 15, 2005
				First Named Inventor	DeKoning et al.
				Art Unit	1614
				Examiner Name	Lawrence E. Crane
				Attorney Docket Number	Docket 067670-5004-US

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	c8	Ichiba et al. "Characterization of GFR, a novel guanine nucleotide exchange factor for Rap1" <i>FEBS Letters</i> (1999) Vol. 457:85-89		
	c9	McPhee et al. "Use of an activation-specific probe to show that Rap1A and Rap1B display different sensitivities to activation for forskolin in Rat1 cells" <i>FEBS Letters</i> (2000) Vol. 477: 213-218		
	c10	Rooij et al. "Epac is a Rap 1 quanine-nucleotide-exchange factor directly activated by cyclic AMP" <i>Nature</i> (1998) Vol. 396: 474-477		

1-SF/7631038.1

Examiner Signature	/Lawrence Crane/	Date Considered	03/18/2010
--------------------	------------------	-----------------	------------

\*EXAMINER: <sup>1</sup> These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./